Hims & Hers Health Inc. reported a first-quarter loss and sales that missed Wall Street estimates as it faces higher costs associated with its strategic pivot to branded weight-loss medications.
Hims & Hers Health Inc. reported a first-quarter loss and sales that missed Wall Street estimates as it faces higher costs associated with its strategic pivot to branded weight-loss medications.
The Hers app arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025. A Super Bowl ad touting Hims & Hers Health Inc.'s copycat weight-loss drugs is getting pushback from the branded drugmakers' lobbying group, which says it's "misleading" and potentially violates marketing rules.
Hims & Hers Health Inc. shares posted their best week on record as a new partnership with Novo Nordisk A/S fuels fresh optimism about the company’s future in weight-loss drugs.
Hims & Hers Health Inc. shares posted their best week on record as a new partnership with Novo Nordisk A/S fuels fresh optimism about the company’s future in weight-loss drugs.
The Hims logo. Photographer: Gabby Jones/Bloomberg
Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that spiraled into a legal battle last month.
Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that spiraled into a legal battle last month.
Bloomberg News Health Reporter Madison Muller reports on the latest on Novo's lawsuit. - Novo Nordisk said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the US patent on semaglutide, the active ingredient in Novo’s blockbuster obesity treatments, Novo argued Monday. The US lawsuit attacks not only Hims’ new strategy to launch a copycat pill but also goes after shot
Bloomberg News Health Reporter Madison Muller reports on the latest on Novo's lawsuit. - Novo Nordisk said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the US patent on semaglutide, the active ingredient in Novo’s blockbuster obesity treatments, Novo argued Monday. The US lawsuit attacks not only Hims’ new strategy to launch a copycat pill but also goes after shots that mimic Wegovy and its sister drug Ozempic.
The move marks a more aggressive approach for Novo under Chief Executive Officer Mike Doustdar. Until now, the drugmaker’s legal strategy focused on the way that companies like Hims market their products. Novo said this is the first time it has sued over patent infringement for compounded semaglutide. (Source: Bloomberg)
Novo Nordisk A/S shares rose after Hims & Hers Health Inc. agreed to stop selling a copycat version of the new Wegovy weight-loss pill following US government threats to crack down on knockoffs. Bloomberg's Sam Fazeli reports. (Source: Bloomberg)
Novo Nordisk A/S shares rose after Hims & Hers Health Inc. agreed to stop selling a copycat version of the new Wegovy weight-loss pill following US government threats to crack down on knockoffs. Bloomberg's Sam Fazeli reports. (Source: Bloomberg)
Novo’s shares plunged on Thursday after telehealth firm Hims & Hers Health Inc. launched a cheaper copycat version of its Wegovy pill that the Danish drugmaker says is illegal. Michael Shah of Bloomberg Intelligence has more. (Source: Bloomberg)
Novo’s shares plunged on Thursday after telehealth firm Hims & Hers Health Inc. launched a cheaper copycat version of its Wegovy pill that the Danish drugmaker says is illegal. Michael Shah of Bloomberg Intelligence has more. (Source: Bloomberg)
Anmelden
